Causes of death and early life determinants of survival in homozygous sickle cell disease: The Jamaican cohort study from birth

Abstract

Globally, the majority of persons born with sickle cell disease do not have access to hydroxyurea or more expensive interventions. The objectives were to estimate the survival in homozygous sickle cell disease, unbiased by symptomatic selection and to ascertain the causes of death in a pre-hydroxyurea population. The utility of early life biomarkers and genetically determined phenotypes to predict survival was assessed. A cohort study based on neonatal diagnosis was undertaken at the Sickle Cell Unit, a specialist clinic delivering care to persons with sickle cell disease in Jamaica. Screening of 100,000 deliveries detected 315 babies with homozygous sickle cell disease of whom 311 have been followed from birth for periods up to 43 years. Pneumococcal prophylaxis and teaching mothers splenic palpation were important, inexpensive interventions. Anticipatory guidance, routine care and out-patient acute care were provided. Each participant was classified as alive, dead, or defaulted (usually emigration). Causes of death were ascertained from clinical records and/or post-mortem reports. Survival was assessed using the Kaplan-Meier function. Sex-adjusted Cox semi-parametric proportional hazards and Weibull modelling were used to assess the effects on survival of biomarkers.Survival to 40 years was 55.5% (95% CI 48.7% to 61.7%). Acute Chest Syndrome (n = 31) and septicemia (n = 14) were significant causes of death at all ages. Acute splenic sequestration (n = 12) was the most common cause of early deaths. Survival was significantly shorter in those with lower hemoglobin at 1 year, high total nucleated count at 1 year, and a history of dactylitis ever.In these hydroxyurea naïve patients, survival into midlife was common. Causes of death were often age specific and some may be preventable. Early life biomarkers predictive of decreased survival in SS disease identify a patient group likely to benefit from close clinical supervision and potentially high risk therapies.

Leg ulcer induced by hydroxycarbamide in sickle cell disease: What is the therapeutic impact?

“…Its use in the prevention of vaso‐occlusive incidents in patients with major sickle syndrome is more recent, producing a reduction in the frequency and severity of crises . Observations suggest it has an impact on mortality . Favourable impact on the prevention of degenerative complications is more difficult to pin down, but it seems probable and requires further long‐term studies .…”

Fatores de risco para mortalidade em pacientes com doença falciforme: uma revisão integrativa

“…43 Regarding risk factors, a total of 10 laboratory variables were identified. The decreased red blood cell count, evidenced by low hematocrit percentage, besides the low Hb level and reticulocytosis 34,44,45 present themselves as risk factors for death in several researches, as well as a higher average corpuscular volume. 46 The increasing white cell numbers 44,45,47,48 have also been associated with a higher risk of death.…”

Splenectomy in sickle cell haemoglobinopathies

“…The splenic complications lie behind the major part of the pathological events in the early life of sickle cell disease patients which are acute sequestration, hypersplenism, splenic infarction leading to functional asplenia, splenic abscess. Acute splenic sequestration crisis is known to be the most common cause of early deaths in these patients 3 .…”